论文已发表
提 交 论 文
注册即可获取Ebpay生命的最新动态
注 册
IF 收录期刊
Authors Si TM, Tan QR, Zhang KR, Wang Y, Rui Q
Published Date January 2015 Volume 2015:11 Pages 87—95
DOI http://dx.doi.org/10.2147/NDT.S70694
Received 6 July 2014, Accepted 30 September 2014, Published 6 January 2015
Background: Antipsychotic
medications facilitate the improvement of psychotic symptoms in patients with
first-episode psychosis. Paliperidone extended-release (pali-ER), an atypical
antipsychotic, was assessed for efficacy and safety in Chinese patients with
first-episode psychosis.
Methods: In this 8-week,
open-label, single-arm, multicenter study, patients with first-episode
psychosis (Diagnostic and Statistical Manual of Mental
Disorders, Fourth Edition criteria) and a Positive and Negative
Syndrome Scale (PANSS) total score ≥70 were treated with flexible-dose pali-ER
tablets (3–12 mg/day). The primary efficacy endpoint was the percentage of
patients with an increase of ≥8 points in Personal and Social Performance (PSP)
score from baseline to day 56 (8 weeks). Secondary endpoints included reduction
in PANSS total score, improvement in Clinical Global Impression-Severity score,
PSP score, Subjective Well-being under Neuroleptics Scale score, and relationship
between duration of untreated psychosis and PANSS or PSP. Incidences of
treatment-emergent adverse events were used to evaluate safety.
Results: Overall, 283 of 294
patients (96%) achieved a ≥8-point increase in PSP (primary endpoint, analysis
set). For the secondary efficacy endpoints, 284/306 patients (93%) had a ≥30%
reduction in PANSS total score; 266/306 patients (87%) achieved a ≤3 Clinical
Global Impression-Severity scale score, and 218/294 patients (74%) had a PSP
score ≥71. The Subjective Well-being under Neuroleptics Scale score was
improved from a baseline mean of 72.7 to 94.7 at endpoint. There was a negative
correlation between duration of untreated psychosis and posttreatment PSP score
and a positive correlation with posttreatment PANSS total score. The most
common treatment-emergent adverse events were extrapyramidal symptoms (12%),
and agitation, somnolence, and xerostomia (4% each).
Conclusion: An 8-week,
flexible-dose (3–12 mg/day) treatment with pali-ER resulted in significant
improvements in psychotic symptoms and social functioning in Chinese patients
with first-episode psychosis and was generally tolerable.
Keywords: paliperidone,
first-episode psychosis, Personal and Social Performance score